UBS Analysts Give Bayer (BAYN) a €125.00 Price Target
UBS set a €125.00 ($148.81) price target on Bayer (FRA:BAYN) in a research note released on Monday morning, www.boersen-zeitung.de reports. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other research analysts have also recently issued reports on the company. Barclays set a €105.00 ($125.00) price target on Bayer and gave the stock a sell rating in a research note on Friday, November 17th. Sanford C. Bernstein set a €131.00 ($155.95) price target on Bayer and gave the stock a buy rating in a research note on Wednesday, November 15th. Commerzbank set a €124.00 ($147.62) price target on Bayer and gave the stock a buy rating in a research note on Wednesday, November 15th. Societe Generale set a €117.00 ($139.29) price target on Bayer and gave the stock a neutral rating in a research note on Tuesday, November 14th. Finally, DZ Bank reissued a buy rating on shares of Bayer in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of €122.43 ($145.75).
Bayer (BAYN) opened at €108.05 ($128.63) on Monday. Bayer has a 52 week low of €86.06 ($102.45) and a 52 week high of €123.82 ($147.40).
ILLEGAL ACTIVITY WARNING: “UBS Analysts Give Bayer (BAYN) a €125.00 Price Target” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/29/ubs-analysts-give-bayer-bayn-a-125-00-price-target.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.